Patents Represented by Attorney, Agent or Law Firm Charles K. Sholtz
-
Patent number: 5846832Abstract: Apparatus and method for producing a defined size distribution of polynucleotide fragments having a selected mean size range between about 100 and 20,000 base pairs. The method includes passing a suspension of polynucleotide fragments through an apparatus containing a capillary with an orifice near the outlet end of the capillary.Type: GrantFiled: September 20, 1996Date of Patent: December 8, 1998Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Peter Josef Oefner, Scott P. Hunicke-Smith
-
Patent number: 5824483Abstract: Combinatorial libraries of different-sequence peptide members is disclosed. The libraries are comprised of stabilized, alpha-helical polypeptides having a similar tertiary structure but different amino acid residues at specific, "variable" positions in the sequence. The polypeptides are stabilized through coiled-coil interactions with other .alpha.-helical polypeptides and/or via intrahelical lactam bridges. Also disclosed are methods for using such libraries to screen for selected macromolecular ligands.Type: GrantFiled: June 16, 1995Date of Patent: October 20, 1998Assignee: Pence Inc.Inventors: Michael E. Houston, Jr., Robert S. Hodges
-
Patent number: 5824649Abstract: Viral proteins derived from an enterically transmitted non-A/non-B viral hepatitis agent (HEV) are disclosed. In one embodiment, the protein is immunologically reactive with antibodies present in individuals infected with the viral hepatitis agent. This protein is useful in a diagnostic method for detecting infection by the enterically transmitted agent. Specific epitopes have been identified that are reactive with sera of individual infected with different strains of HEV. Also disclosed are DNA probes derived from a cloned sequence of the viral agent. These probes are useful for identifying and sequencing the entire viral agent and for assaying the presence of the viral agent in an infected sample, by using probe-specific amplification of virus-derived DNA fragments.Type: GrantFiled: June 7, 1995Date of Patent: October 20, 1998Assignee: Genelabs Technologies, Inc.Inventors: Gregory R. Reyes, Patrice O. Yarbough, Daniel W. Bradley, Krzysztof Z. Krawczynski, Albert Tam, Kirk E. Fry
-
Patent number: 5821091Abstract: A method of identifying the presence of activated T-cells in a sample containing a plurality of different cell types is disclosed. The method includes the detection of polynucleotide sequences selectively expressed in activated T-cells.Type: GrantFiled: January 26, 1996Date of Patent: October 13, 1998Assignee: Genelabs Technologies, Inc.Inventor: Gregory Dolganov
-
Patent number: 5789559Abstract: Nucleic acid sequences derived from enterically transmitted nonA/nonB viral hepatitis agent (HEV) are disclosed. DNA sequences encoding specific epitopes within viral protein sequences that are reactive with sera of individuals infected with different strains of HEV are also disclosed. These DNA sequences and fragments thereof are useful for identifying and sequencing the entire viral agent and for assaying the presence of the viral agent in an infected sample, for example by using specific amplification of virus-derived DNA sequences, as well as for producing viral proteins or polypeptides.Type: GrantFiled: July 25, 1994Date of Patent: August 4, 1998Assignee: Genelabs Technologies, Inc.Inventors: Gregory R. Reyes, Patrice O. Yarbough, Daniel W. Bradley, Krzysztof Z. Krawczynski, Albert Tam, Kirk E. Fry
-
Patent number: 5783383Abstract: The present invention provides methods and compositions relating to cytomegalovirus (CMV) latent transcripts, latency-associated polypeptides and antibodies directed against such polypeptide. The polypeptides are encoded by CMV DNA sequences and are produced specifically during latent infection. Also provided are methods of detecting CMV in a sample, particularly CMV in a latent state. The methods include RT-PCR-based methods and immunodiagnostic methods.Type: GrantFiled: May 23, 1995Date of Patent: July 21, 1998Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Kazuhiro Kondo, Edward S. Mocarski, Jr.
-
Patent number: 5770690Abstract: Bax-.omega. polynucleotides and polypeptides, and compositions effective to hybridize to Bax-.omega. polynucleotides are disclosed. Also disclosed are methods for altering apoptosis in cells, for promoting cell survival and for identifying compounds capable of affecting the binding of Bax-.omega. to other proteins involved in apoptosis.Type: GrantFiled: March 15, 1996Date of Patent: June 23, 1998Assignee: Neurex CorporationInventors: Catherine Mastroni Bitler, Stephen Scott Bowersox, Roberto Crea, Susan Dunham Demo, William A. Horne, Mei Zhou
-
Patent number: 5753434Abstract: Methods and compositions effective to alter the sexual or reproductive behavior of an insect are disclosed. The compositions include polynucleotides and polypeptides corresponding to the fru gene in Drosophila and its homologs in other species. Methods of identifying a compound effective to alter the reproductive behavior of an insect are also disclosed.Type: GrantFiled: February 10, 1995Date of Patent: May 19, 1998Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Lisa C. Ryner, Bruce S. Baker, Steven A. Wasserman, Diego H. Castrillon
-
Patent number: 5741490Abstract: Antigen and antibody vaccine composition effective in preventing hepatitis E virus (HEV) infection are disclosed. The antigen composition includes a peptide corresponding to a carboxyl terminal end region of the capsid protein encoded by the second open reading frame 2 of the HEV genome. The composition is effective in preventing HEV infection after vaccination. The antibody composition contains an antibody effective to block HEV infection of human primary hepatocytes in culture.Type: GrantFiled: June 13, 1994Date of Patent: April 21, 1998Assignee: Genelabs Technologies, Inc.Inventors: Gregory R. Reyes, Daniel W. Bradley, Jr-Shin Twu, Michael A. Purdy, Albert W. Tam, Krzysztof Z. Krawczynski, Patrice D. Yarbough
-
Patent number: 5738996Abstract: A combinatorial library composition and method for using the library to construct oligomers effective to bind to a selected ligand is disclosed. The library composition includes at least two sets of ar oligomer libraries, each library set having selected oligomer subunit positions filled by known subunits, and other subunit positions containing permutations of subunits. In the selection method, oligomers from each library set are identified, and a new permutation library formed of subunits corresponding to the highest binding affinity oligomers in each library is screened for binding affinity to the selected ligand.Type: GrantFiled: June 15, 1994Date of Patent: April 14, 1998Assignee: Pence, Inc.Inventors: Robert S. Hodges, Randall T. Irvin, Arne Holm, Wah Y. Wong, Hasmukh B. Sheth, Devon L. Husband
-
Patent number: 5738845Abstract: The present invention describes the production of interferon-.tau. proteins and polypeptides derived therefrom. The antiviral and anticellular proliferation properties of these proteins and polypeptides are disclosed. One advantage of the proteins of the present invention is that they do not have cytotoxic side-effects when used to treat cells. Structure/function relationships for the interferon-.tau. protein are also described. In one aspect, the invention includes ovine interferon-.tau.. In another aspect the invention includes multiple forms of human interferon-.tau..Type: GrantFiled: May 31, 1995Date of Patent: April 14, 1998Assignee: The Women's Research InstituteInventor: Kazuhiko Imakawa
-
Patent number: 5707830Abstract: The present invention describes an expression vector useful for transfection of a selected mammalian host cell. The vector includes the following components: an Epstein Barr Virus (EBV) family of repeats; a copy of the EBV Nuclear Antigen-1 (EBNA-1) gene that can be functionally expressed in the host cell; a eucaryotic DNA fragment, which provides the ability of the vector to replicate in host cells; and an expression cassette which comprises a promoter functional in said host cell, a coding sequence having 5' and 3' ends, where said coding sequence is functionally linked to said promoter, where said 5' end is adjacent the promoter and said 3' end is adjacent transcription termination sequences. The vector of the present invention is useful in the transfection of mammalian cells, including rodent and human cells. The vector is stably retained and replicates in concert with genomic sequences of the host cell, that is, the vector is typically replicated once per cell cycle.Type: GrantFiled: April 2, 1997Date of Patent: January 13, 1998Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventor: Michele Pamela Calos
-
Patent number: 5705363Abstract: The present invention describes the production of interferon-.tau. proteins and polypeptides derived therefrom. The antiviral and anticellular proliferation properties of these proteins and polypeptides are disclosed. One advantage of the proteins of the present invention is that they do not have cytotoxic side-effects when used to treat cells. Structure/function relationships for the interferon-.tau. protein are also described. In one aspect, the invention includes ovine interferon-.tau.. In another aspect the invention includes multiple forms of human interferon-.tau..Type: GrantFiled: May 10, 1995Date of Patent: January 6, 1998Assignee: The Women's Research InstituteInventor: Kazuhiko Imakawa
-
Patent number: 5698685Abstract: A method of generating a compound capable of interacting specifically with a selected macromolecular ligand is disclosed. The method involves contacting the ligand with a combinatorial library of oligomers composed of morpholino subunits with a variety of nucleobase and non-nucleobase side chains. Oligomer molecules that bind specifically to the receptor are isolated and their sequence of base moieties is determined. Also disclosed is a combinatorial library of oligomers useful in the method and novel morpholino-subunit polymer compositions.Type: GrantFiled: March 31, 1995Date of Patent: December 16, 1997Assignee: Antivirals Inc.Inventors: James E. Summerton, Dwight D. Weller
-
Patent number: 5693476Abstract: Methods of identifying compounds capable of affecting binding of a SNAP-25, .alpha.-SNAP, n-sec1 or VAMP to syntaxin are disclosed. Compounds identified by such methods are useful for modulating vesicular release, such as release at neural synapses.Type: GrantFiled: February 24, 1995Date of Patent: December 2, 1997Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventor: Richard H. Scheller
-
Patent number: 5686239Abstract: Peptide antigens are provided which are derived from the enterically transmitted non-A/non-B viral hepatitis agent, known as hepatitis E virus (HEV). The HEV derived peptides and in particular, SG3, are immunoreactive with sera from individuals infected with HEV. The antigens are useful as diagnostic reagents in diagnostic methods and kits for determining infection of an individual with HEV.Type: GrantFiled: May 9, 1994Date of Patent: November 11, 1997Assignee: Genelabs Technologies, Inc.Inventors: Gregory R. Reyes, Albert W. Tam, Patrice O. Yarbough
-
Patent number: 5675061Abstract: The present invention describes vectors and methods useful for the production of transgenic mollusks, in particular, transgenic abalone. The invention further describes transgenic mollusks having enhanced growth properties. In addition, the isolation and characterization of an abalone actin gene promoter region is disclosed.Type: GrantFiled: August 5, 1994Date of Patent: October 7, 1997Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Dennis Alpha Powers, Lynna Madsen Hereford, deceased, Marta Gomez-Chiarri
-
Patent number: 5661033Abstract: Defective herpes simplex virus (HSV) vectors have been used to express a glucose transporter gene. The vectors were propagated using HSV conditional mutants. The efficacy of this system in vivo was tested by microinjection of the vector into adult rat hippocampus and measurement with [.sup.14 C]2-deoxyglucose uptake autoradiography, as well as measurement of kainic acid-(KA-) induced lesions. The vector significantly enhanced glucose transport and decreased neuronal damage in regions near the site of injection without causing adverse cytopathology. Neuroprotection was conferred by injecting the vector prior to, concurrently with, and following neuronal insult.Type: GrantFiled: August 8, 1994Date of Patent: August 26, 1997Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Dora Yuk-wai Ho, Robert Morris Sapolsky, Edward S. Mocarski, Jr.
-
Patent number: 5643742Abstract: This invention provides an improved system for monitoring and recording cell cultures. A method for measuring a delay period for an alternating current voltage applied across a pair of pins improves the stability of measurements made with the improved system. A method for applying a voltage across a pair of pins which avoids exceeding a pre-established voltage avoids the possibility of damaging and/or destroying cells while monitoring their culture.Type: GrantFiled: March 23, 1995Date of Patent: July 1, 1997Assignee: CellStat Technologies, Inc.Inventors: Patricia J. Malin, Kenneth Richard Wada, Oskar Werner Huber
-
Patent number: 5643714Abstract: Novel HTLV-I and HTLV-II peptides are disclosed for use in diagnostic assays for detecting and confirming HTLV-I and HTLV-II infection in human sera. The peptides are derived from analogous regions of HTLV-I and HTLV-II gp21 envelope protein, and are diagnostic of HTLV-I or HTLV-II infection. The invention also includes an assay kit and method for detecting, and discriminating between, HTLV-I and HTLV-II infection in humans.Type: GrantFiled: February 5, 1993Date of Patent: July 1, 1997Assignees: Genelabs Technologies, Inc., The Board of Trustees of the Leland Stanford Junior UniversityInventors: Kenneth G. Hadlock, Chin-Joo Goh, Steven K.H. Foung